Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

Overview of attention for article published in Neuro-Oncology, May 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#11 of 3,703)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 47 news outlets
twitter: 24 X users

facebook: 1 Facebook page

Readers on

mendeley: 155 Mendeley

So far, Altmetric has seen 28 X posts from 24 X users, with an upper bound of 55,694 followers.

RT @cyrusbiotech: Rosetta software optimized enzyme cancer therapy with positive clinical results from @Tocagen https://t.co/KMuDVAbATz

RT @UWproteindesign: We are thrilled to see these cancer-fighting results from a Rosetta-optimized enzyme currently undergoing clinical tri…

RT @cyrusbiotech: Rosetta software optimized enzyme cancer therapy with positive clinical results from @Tocagen https://t.co/KMuDVAbATz

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 24 additional X posts.